Histogen Inc logo

HSTO - Histogen Inc News Story

$0.71 -0.0  -3.0%

Last Trade - 27/10/21

Sector
Healthcare
Size
Micro Cap
Market Cap £22.2m
Enterprise Value £4.68m
Revenue £1.02m
Position in Universe 6384th / 7275

BRIEF-Histogen And Amerimmune Announce Additional Findings From Its Phase 1 Study Of Emricasan In Mild Symptomatic Covid-19 Patients

Mon 16th August, 2021 1:21pm
Aug 16 (Reuters) - Histogen Inc  HSTO.O :
    * HISTOGEN AND AMERIMMUNE ANNOUNCE ADDITIONAL FINDINGS FROM
ITS
PHASE 1 STUDY OF EMRICASAN IN MILD SYMPTOMATIC COVID-19 PATIENTS
    * HISTOGEN - ADDITIONAL FINDINGS FURTHER REINFORCE THAT
EMRICASAN
CAN POTENTIALLY BE DEVELOPED AS A THERAPEUTIC TREATMENT FOR MILD
TO MODERATE COVID-19

Source text for Eikon:  ID:nGNX6l98b6 
Further company coverage:  HSTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.